TargeGen Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $201M

TargeGen General Information

Description

Developer of small molecule kinase inhibitors that target vascular leakage (edema), vascular proliferation (angiogenesis), and inflammation. The company offers its products for the treatment of human diseases, such as heart attack, cancer, and eye diseases; vascular leakage, edema, and the unwanted growth of new blood vessels; pleural effusions, arthritis, pulmonary edema, transplant ischemia, ARDS, brain inflammation, hypovolemia (acute blood loss) CNS disorders, and other serious medical conditions.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 9380 Judicial Drive
  • San Diego, CA 92121
  • United States
+1 (858)
Primary Industry
Pharmaceuticals
Acquirer
Sanofi
Vertical(s)
Corporate Office
  • 9380 Judicial Drive
  • San Diego, CA 92121
  • United States
+1 (858)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

TargeGen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 21-Jul-2010 $201M Completed Clinical Trials - Phase 1
4. Later Stage VC (Series D) 12-Jul-2007 Completed Clinical Trials - Phase 1
3. Later Stage VC (Series C) 31-Aug-2005 Completed Generating Revenue
2. Early Stage VC (Series B) 13-Jan-2004 $30.6M $40.6M Completed Generating Revenue
1. Early Stage VC (Series A) 03-Apr-2002 $10M $10M Completed Product Development
To view TargeGen’s complete valuation and funding history, request access »

TargeGen Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D
Series C
Series B 27,061,947 $0.000100 $0.09 $1.13 $1.13 1x $1.13 22.55%
Series A 10,000,000 $0.000100 $0.08 $1 $1 1x $1 8.33%
To view TargeGen’s complete cap table history, request access »

TargeGen Former Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
BB Biotech Ventures Venture Capital Minority
CDIB Capital Group Asset Manager Minority
CTI Life Sciences Fund Venture Capital Minority
Chicago Growth Partners PE/Buyout Minority
Enterprise Partners Venture Capital Venture Capital Minority
You’re viewing 5 of 12 investors. Get the full list »

TargeGen FAQs

  • When was TargeGen founded?

    TargeGen was founded in 2002.

  • Where is TargeGen headquartered?

    TargeGen is headquartered in San Diego, CA.

  • What industry is TargeGen in?

    TargeGen’s primary industry is Pharmaceuticals.

  • Is TargeGen a private or public company?

    TargeGen is a Private company.

  • What is the current valuation of TargeGen?

    The current valuation of TargeGen is .

  • What is TargeGen’s current revenue?

    The current revenue for TargeGen is .

  • How much funding has TargeGen raised over time?

    TargeGen has raised $111M.

  • Who are TargeGen’s investors?

    BB Biotech Ventures, CDIB Capital Group, CTI Life Sciences Fund, Chicago Growth Partners, and Enterprise Partners Venture Capital are 5 of 12 investors who have invested in TargeGen.

  • When was TargeGen acquired?

    TargeGen was acquired on 21-Jul-2010.

  • Who acquired TargeGen?

    TargeGen was acquired by Sanofi.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process